HomeCompareSEEL vs EPRT

SEEL vs EPRT: Dividend Comparison 2026

SEEL yields 540.54% · EPRT yields 3.92%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SEEL wins by $112786.16M in total portfolio value
10 years
SEEL
SEEL
● Live price
540.54%
Share price
$0.37
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$112786.22M
Annual income
$82,692,515,806.61
Full SEEL calculator →
EPRT
EPRT
● Live price
3.92%
Share price
$30.77
Annual div
$1.21
5Y div CAGR
29%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$63.4K
Annual income
$12,840.73
Full EPRT calculator →

Portfolio growth — SEEL vs EPRT

📍 SEEL pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSEELEPRT
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SEEL + EPRT cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SEEL pays
EPRT pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SEEL
Annual income on $10K today (after 15% tax)
$45,945.95/yr
After 10yr DRIP, annual income (after tax)
$70,288,638,435.62/yr
EPRT
Annual income on $10K today (after 15% tax)
$332.87/yr
After 10yr DRIP, annual income (after tax)
$10,914.62/yr
At 15% tax rate, SEEL beats the other by $70,288,627,521.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SEEL + EPRT for your $10,000?

SEEL: 50%EPRT: 50%
100% EPRT50/50100% SEEL
Portfolio after 10yr
$56393.14M
Annual income
$41,346,264,323.67/yr
Blended yield
73.32%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EPRT right now

SEEL
Analyst Ratings
6
Buy
2
Hold
Consensus: Buy
Altman Z
-156.6
Piotroski
5/9
EPRT
Analyst Ratings
1
Strong
17
Buy
3
Hold
1
Sell
Consensus: Buy
Price Target
$35.50
+15.4% upside vs current
Range: $33.00 — $37.00
Altman Z
1.8
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SEEL buys
0
EPRT buys
0
No recent congressional trades found for SEEL or EPRT in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSEELEPRT
Forward yield540.54%3.92%
Annual dividend / share$2.00$1.21
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%29%
Portfolio after 10y$112786.22M$63.4K
Annual income after 10y$82,692,515,806.61$12,840.73
Total dividends collected$110217.05M$37.9K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusBuyBuy

Year-by-year: SEEL vs EPRT ($10,000, DRIP)

YearSEEL PortfolioSEEL Income/yrEPRT PortfolioEPRT Income/yrGap
1← crossover$64,754$54,054.05$11,205$505.18+$53.5KSEEL
2$396,410$327,123.28$12,672$682.46+$383.7KSEEL
3$2,295,726$1,871,567.31$14,490$930.48+$2.28MSEEL
4$12,586,137$10,129,710.14$16,786$1,282.69+$12.57MSEEL
5$65,369,349$51,902,182.37$19,753$1,791.56+$65.35MSEEL
6$321,877,325$251,932,121.38$23,677$2,541.64+$321.85MSEEL
7$1,503,762,535$1,159,353,797.14$29,008$3,672.99+$1503.73MSEEL
8$6,671,013,644$5,061,987,731.83$36,463$5,425.08+$6670.98MSEEL
9$28,124,961,234$20,986,976,635.20$47,238$8,221.57+$28124.91MSEEL
10$112,786,224,327$82,692,515,806.61$63,385$12,840.73+$112786.16MSEEL

SEEL vs EPRT: Complete Analysis 2026

SEELStock

Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for the treatment of patients with Parkinson's disease (PD). Its preclinical programs include SLS-007, an anti-alpha-synuclein peptidic inhibitor to treat patients with PD; SLS-008, an orally available antagonist for chemoattractant receptor-homologous molecule for the treatment of chronic inflammation in asthma and pediatric orphan indications; SLS-004 for the treatment of PD; SLS-010, an oral histamine H3A receptor antagonist for narcolepsy and related disorders; and SLS-012, an injectable therapy for post-operative pain management. Seelos Therapeutics, Inc. was incorporated in 1987 and is headquartered in New York, New York.

Full SEEL Calculator →

EPRTREIT

Essential Properties Realty Trust, Inc., a real estate company, acquires, owns, and manages single-tenant properties in the United States. The company leases its properties to middle-market companies, such as restaurants, car washes, automotive services, medical and dental services, convenience stores, equipment rental, entertainment, early childhood education, grocery, and health and fitness on a long-term basis. As of December 31, 2021, it had a portfolio of 1, 451 properties. The company qualifies as a real estate investment trust for federal income tax purposes. It generally would not be subject to federal corporate income taxes if it distributes at least 90% of its taxable income to its stockholders. The company was founded in 2016 and is headquartered in Princeton, New Jersey.

Full EPRT Calculator →
📬

Get this SEEL vs EPRT comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SEEL vs SCHDSEEL vs JEPISEEL vs OSEEL vs KOSEEL vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.